[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab-Reference-Cited by-同舟云学术

[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab

Published:2023-08-22 Issue:13 Volume:50 Page:4024-4035
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Seban Romain-David^ORCID,Arnaud Emilie,Loirat Delphine,Cabel Luc,Cottu Paul,Djerroudi Lounes,Hescot Segolene,Loap Pierre,Bonneau Claire,Bidard Francois-Clement,Huchet Virginie,Jehanno Nina,Berenbaum Arnaud,Champion Laurence,Buvat Irene

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06394-y.pdf

Reference39 articles.

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.

2. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485–505.

3. Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497–508.

4. Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381.

5. Telli M. Evolving treatment strategies for triple-negative breast cancer. J Natl Compr Canc Netw. 2015;13:652–4.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of prognostic risk factors of triple-negative breast cancer with 18F-FDG PET/CT parameters, clinical pathological features and biochemical indicators;Frontiers in Cell and Developmental Biology;2024-09-04

2. Use of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy;Radiology;2024-09-01

3. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-07

4. A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma;Frontiers in Immunology;2024-06-14

5. Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review;Translational Lung Cancer Research;2024-05